Bank Of America Corp Provention Bio, Inc. Transaction History

Bank Of America Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$6.7 - $24.21 $330,973 - $1.2 Million	49,399 Added 99.38%	99,105 $2.39 Million
Q4 2022 Feb 10, 2023	SELL	$4.52 - $10.57 $78,968 - $184,668	-17,471 Reduced 26.01%	49,706 $525,000
Q3 2022 Nov 14, 2022	SELL	$3.43 - $5.62 $25,670 - $42,060	-7,484 Reduced 10.02%	67,177 $303,000
Q2 2022 Aug 12, 2022	BUY	$3.65 - $7.3 $79,427 - $158,855	21,761 Added 41.14%	74,661 $298,000
Q1 2022 May 16, 2022	SELL	$3.4 - $7.88 $169,748 - $393,416	-49,926 Reduced 48.55%	52,900 $388,000
Q4 2021 Feb 08, 2022	BUY	$5.59 - $7.39 $350,632 - $463,537	62,725 Added 156.42%	102,826 $578,000
Q3 2021 Nov 15, 2021	BUY	$5.66 - $8.33 $16,402 - $24,140	2,898 Added 7.79%	40,101 $256,000
Q2 2021 Sep 13, 2021	BUY	$6.71 - $11.04 $249,632 - $410,721	37,203 New	37,203 $313,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.